AstraZeneca | Results Presentation Deck | 40 slides

AstraZeneca · 2022-07
arc beats above · slides in the middle · loops below · scroll → 0 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

1
coverage by narrative range · generated from this deck JSON
Narrative range 40 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 40 slides 100% 40/40 slides 100% 40/40 slides · 237 hits
0/40 slides
37.5% 15/40 slides · 18 hits 10% 4/40 slides
0/40 slides
0/40 slides

Slide inventory

40
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
front_matter
04
front_matter
05
The slide uses a three-column layout to categorize performance metrics and clinical pipeline updates.summarize
06
The slide uses a 3-column layout for the top section and a full-width block for the bottom section to categorize strategic initiatives.summarize
07
Includes a comprehensive list of abbreviations at the bottom.summarize
08
front_matter
09
The table provides a detailed breakdown of P&L items including revenue segments, operating expenses, and profitability metrics.analyze_data
10
The slide uses a standard P&L format to demonstrate operating leverage by comparing growth rates of revenue vs expenses.analyze_data
11
CER = constant exchange rates.summarize
12
Includes a specific metric for Net Debt/EBITDA adjusted for inventory fair value uplift.analyze_data
13
introduce_nominees
14
The slide uses a stacked bar chart to show revenue composition by quarter from 2020 to H1 2022, alongside a list of key business dynamics and a table of upcominanalyze_data
15
Includes clinical trial data (KM curves, hazard ratios, median OS) and strategic updates.summarize
16
Includes a pie chart of resistance mechanisms and a table of clinical trial cohorts.summarize
17
Features corporate branding and a molecular visualization.introduce_nominees
18
Slide 18 of a presentation, likely AstraZeneca H1 2022 results.analyze_data
19
Includes detailed footnotes regarding pro-forma calculations and definitions of regional segments.analyze_data
20
Includes a detailed list of medical abbreviations in the footer.summarize
21
Includes a screenshot of a NEJM research summary and a list of key clinical/regulatory milestones.summarize
22
The slide features a headshot of the speaker and a molecular visualization, typical of a section divider or speaker introduction.introduce_nominees
23
The slide uses a stacked bar chart to show revenue composition over six quarters and a bulleted list to explain the underlying business dynamics.analyze_data
24
The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy and a list to show upcoming regulatory milestones.analyze_data
25
The slide serves as a transition or closing marker for a presentation.summarize
26
introduce_nominees
27
The slide uses a four-pillar framework to summarize growth drivers.summarize
28
introduce_nominees
30
The slide uses a three-column layout to categorize ESG achievements with corresponding footnotes.summarize
31
The slide uses a matrix structure to map regulatory milestones against time periods.analyze_data
32
Includes legend for disease areas and geographies; footnotes clarify reporting changes for Koselugo and Andexxa.analyze_data
33
The slide displays two stacked bar charts with corresponding data tables below each chart.analyze_data
34
The slide contains two distinct bar charts with corresponding data tables.analyze_data
35
The slide shows stacked bar charts for two products with corresponding data tables below each chart.analyze_data
36
Data presented in stacked bar charts with corresponding data tables below each chart.analyze_data
37
The slide displays two stacked bar charts with corresponding data tables below each chart.analyze_data
38
The slide shows stacked bar charts with corresponding data tables for two products.analyze_data
39
Data reflects revenues booked by AstraZeneca post-acquisition of Alexion on 21 July 2021.analyze_data